SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio ® long-term continuous ECG monitoring (LTCM) system, ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Heart health issues are intermittent and often asymptomatic, leaving issues undetected with individuals unaware of any underlying problem. This presents itself in places where we least expect them, ...

iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions. Large-scale analysis of more than 400,000 ...

iRhythm Technologies, Inc. IRTC has received regulatory approval from Japan’s Pharmaceutical and Medical Device Agency for its Zio long-term continuous ECG monitoring (LTCM) system. The Zio system, ...

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) (NASDAQ:IRTC) today announced initial research findings on post-market, real-world performance of Zio ® monitor, its ...

According to the Centers for Disease Control (CDC), approximately 610,000 people die of heart disease in the U.S. every year — that’s one in every four deaths 1. Cardiac health is one of the most ...

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that Radius VSM™, a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance. Designed on ...

BELLEVUE, Wash.--(BUSINESS WIRE)--Cardiac Insight, Inc., creators of Cardea SOLO™ prescription cardiac sensors and automated electrocardiography (ECG) Analysis Software, shares its perspective on the ...